An Appraisal of the Current Scenario in Vaccine Research for COVID-19

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2021 Aug 10

PMID 34372603

Citations 2

Authors

Wai Chin Chong

Dinesh K Chellappan

Shakti D Shukla

Gregory M Peterson

Rahul P Patel

Niraj Kumar Jha

Rajaraman D Eri

Kamal Dua

Murtaza M Tambuwala

Madhur D Shastri

Affiliations

Soon will be listed here.

Abstract

The recent coronavirus disease 2019 (COVID-19) outbreak has drawn global attention, affecting millions, disrupting economies and healthcare modalities. With its high infection rate, COVID-19 has caused a colossal health crisis worldwide. While information on the comprehensive nature of this infectious agent, SARS-CoV-2, still remains obscure, ongoing genomic studies have been successful in identifying its genomic sequence and the presenting antigen. These may serve as promising, potential therapeutic targets in the effective management of COVID-19. In an attempt to establish herd immunity, massive efforts have been directed and driven toward developing vaccines against the SARS-CoV-2 pathogen. This review, in this direction, is aimed at providing the current scenario and future perspectives in the development of vaccines against SARS-CoV-2.

Citing Articles

In-silico screening and in-vitro assay show the antiviral effect of Indomethacin against SARS-CoV-2.

Chakraborty R, Bhattacharje G, Baral J, Manna B, Mullick J, Mathapati B Comput Biol Med. 2022; 147:105788.

PMID: 35809412 PMC: 9245396. DOI: 10.1016/j.compbiomed.2022.105788.

COVID-19 in 2021.

Lundstrom K, Aljabali A Viruses. 2021; 13(10).

PMID: 34696528 PMC: 8539425. DOI: 10.3390/v13102098.

References

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Monto A, Ohmit S, Petrie J, Johnson E, Truscon R, Teich E . Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med. 2009; 361(13):1260-7. DOI: 10.1056/NEJMoa0808652. View

Roman G, Gracia F, Torres A, Palacios A, Gracia K, Harris D . Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222). Front Immunol. 2021; 12:653786. PMC: 8107358. DOI: 10.3389/fimmu.2021.653786. View

Mahase E . Covid-19: Russia approves vaccine without large scale testing or published results. BMJ. 2020; 370:m3205. DOI: 10.1136/bmj.m3205. View

Roozendaal R, Solforosi L, Stieh D, Serroyen J, Straetemans R, Dari A . SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques. Nat Commun. 2021; 12(1):5877. PMC: 8497464. DOI: 10.1038/s41467-021-26117-x. View

Tan M, Jiang X . Recent advancements in combination subunit vaccine development. Hum Vaccin Immunother. 2016; 13(1):180-185. PMC: 5287306. DOI: 10.1080/21645515.2016.1229719. View

Garcia-Beltran W, Lam E, St Denis K, Nitido A, Garcia Z, Hauser B . Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021; 184(9):2372-2383.e9. PMC: 7953441. DOI: 10.1016/j.cell.2021.03.013. View

Deng X, Garcia-Knight M, Khalid M, Servellita V, Wang C, Morris M . Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell. 2021; 184(13):3426-3437.e8. PMC: 8057738. DOI: 10.1016/j.cell.2021.04.025. View

Tiede A, Sachs U, Czwalinna A, Werwitzke S, Bikker R, Krauss J . Prothrombotic immune thrombocytopenia after COVID-19 vaccination. Blood. 2021; 138(4):350-353. PMC: 8084604. DOI: 10.1182/blood.2021011958. View

10.

Hirotsu Y, Omata M . Discovery of a SARS-CoV-2 variant from the P.1 lineage harboring K417T/E484K/N501Y mutations in Kofu, Japan. J Infect. 2021; 82(6):276-316. PMC: 7985610. DOI: 10.1016/j.jinf.2021.03.013. View

11.

van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham J, Port J . ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020; 586(7830):578-582. PMC: 8436420. DOI: 10.1038/s41586-020-2608-y. View

12.

Corbett K, Flynn B, Foulds K, Francica J, Boyoglu-Barnum S, Werner A . Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med. 2020; 383(16):1544-1555. PMC: 7449230. DOI: 10.1056/NEJMoa2024671. View

13.

Paavonen J, Naud P, Salmeron J, Wheeler C, Chow S, Apter D . Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009; 374(9686):301-14. DOI: 10.1016/S0140-6736(09)61248-4. View

14.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

15.

Shastri M, Shukla S, Chong W, Kc R, Dua K, Patel R . Smoking and COVID-19: What we know so far. Respir Med. 2020; 176:106237. PMC: 7674982. DOI: 10.1016/j.rmed.2020.106237. View

16.

Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B . Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021; 384(23):2187-2201. PMC: 8220996. DOI: 10.1056/NEJMoa2101544. View

17.

Volz E, Hill V, McCrone J, Price A, Jorgensen D, OToole A . Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity. Cell. 2020; 184(1):64-75.e11. PMC: 7674007. DOI: 10.1016/j.cell.2020.11.020. View

18.

Edara V, Pinsky B, Suthar M, Lai L, Davis-Gardner M, Floyd K . Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants. N Engl J Med. 2021; 385(7):664-666. PMC: 8279090. DOI: 10.1056/NEJMc2107799. View

19.

Folegatti P, Ewer K, Aley P, Angus B, Becker S, Belij-Rammerstorfer S . Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249):467-478. PMC: 7445431. DOI: 10.1016/S0140-6736(20)31604-4. View

20.

Abu-Raddad L, Chemaitelly H, Butt A . Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N Engl J Med. 2021; 385(2):187-189. PMC: 8117967. DOI: 10.1056/NEJMc2104974. View